Search

Alkermes PLC

Закрыт

СекторЗдравоохранение

48.84 1.1

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

47.47

Макс.

49

Ключевые показатели

By Trading Economics

Доход

67M

501K

Продажи

103M

496M

P/E

Средняя по отрасли

131.184

57.371

Прибыль на акцию

0.52

Рентабельность продаж

0.101

Сотрудники

2,050

EBITDA

76M

54M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+20.53% upside

Дивиденды

By Acuity

Следующий отчет о доходах

27 окт. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-426M

8.4B

Предыдущая цена открытия

47.74

Предыдущая цена закрытия

48.84

Новостные настроения

By Acuity

10%

90%

8 / 340 Рейтинг в Healthcare

Alkermes PLC График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

21 авг. 2026 г., 19:51 UTC

Alkermes Plc's shares are higher, supported by strong biotechnology sector momentum, though the stock is pulling back from earlier session highs.

20 авг. 2026 г., 20:01 UTC

Alkermes Plc shares are lower, impacted by broader weakness in the Biotechnology sector. The stock is trading below its 20-day moving average.

19 авг. 2026 г., 19:26 UTC

Alkermes Plc is trading higher, maintaining momentum since Tuesday's close, despite no specific news driving the price movement.

18 авг. 2026 г., 19:16 UTC

News

Alkermes Plc shares are lower after an insider sold 7,576 shares at prices between $49.19 and $49.65, raising investor concerns about the outlook.

17 авг. 2026 г., 23:31 UTC

Alkermes Plc shares are higher in after-market trading, reflecting a cumulative gain since Monday's close amid broader market volatility and fluctuating crude oil prices.

14 авг. 2026 г., 19:46 UTC

Alkermes Plc shares are lower today amid broader market weakness following a reported decline in U.S. retail sales for July.

13 авг. 2026 г., 19:26 UTC

Alkermes Plc shares are lower during Thursday's session, breaking a trend of higher closes. Broader market sentiment may be influenced by rising jobless claims.

12 авг. 2026 г., 21:51 UTC

Alkermes shares are higher in after-market trading, reflecting positive momentum amid easing inflation concerns and a broader market recovery.

11 авг. 2026 г., 19:26 UTC

Alkermes Plc shares are trading lower today, remaining near the lower end of their one-month range amid a lack of specific company news.

10 авг. 2026 г., 19:46 UTC

Alkermes shares are advancing today, despite earlier fluctuations and no specific news. Broader market uncertainty follows a decline in U.S. employment reported last Friday.

6 авг. 2026 г., 19:36 UTC

Alkermes Plc shares are lower today, reflecting unusual volatility and trading significantly below the 20-day moving average. No specific news was identified.

5 авг. 2026 г., 19:56 UTC

Alkermes Plc shares are lower Wednesday, continuing a decline since Tuesday's close, despite broader market optimism from falling oil prices and potential diplomatic resolutions.

4 авг. 2026 г., 19:26 UTC

News

Alkermes Plc shares are lower today amid concerns over recent insider sales by executives, despite the company's gross margin of 80.22%.

3 авг. 2026 г., 20:02 UTC

Alkermes shares are higher today, driven by significant gains in the overall market and major technology stocks, despite earlier session pullbacks.

31 июл. 2026 г., 19:36 UTC

Alkermes Plc shares are lower today, impacted by declines in the Biotechnology sub-sector. The stock remains below its 20-day moving average.

30 июл. 2026 г., 19:58 UTC

Alkermes Plc shares are higher during Thursday's session, reflecting a broader recovery in tech shares despite remaining below the 20-day moving average.

29 июл. 2026 г., 20:03 UTC

News
Macro Event

Shares declining despite price target increases from JP Morgan, Baird.

28 июл. 2026 г., 20:02 UTC

News
Event

Alkermes Plc shares are lower after reporting second-quarter earnings of 0 cents per share, below the consensus estimate of 29 cents.

24 июл. 2026 г., 19:46 UTC

Alkermes Plc shares are lower today, pulling back after an early high. No specific news has been identified to explain the decline.

22 июл. 2026 г., 19:36 UTC

Alkermes Plc shares are lower today, despite an earlier session high, amid rising crude oil prices and concerns over potential supply disruptions.

21 июл. 2026 г., 18:46 UTC

Alkermes shares are higher today, supported by improved market sentiment and renewed interest in AI stocks. The asset is trading near its one-month range high.

20 июл. 2026 г., 22:01 UTC

Alkermes Plc shares declined after-market, retracing from earlier peaks. The asset is currently below its 20-day moving average.

Сравнение c конкурентами

Изменение цены

Alkermes PLC Прогноз

Целевая цена

By TipRanks

20.53% рост

Прогноз на 12 месяцев

Средняя 58.25 USD  20.53%

Максимум 65 USD

Минимум 38 USD

Основано на мнении 12 аналитиков Wall Street, спрогнозировавших целевые цены для Alkermes PLC на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

12 ratings

9

Покупка

2

Удержание

1

Продажа

Настроения

By Acuity

8 / 340Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
help-icon Live chat